Expertise in
8
conditions

Ur Metser

200 Elizabeth St, M5G, 2C4, 
Toronto, ON, CA 
Expertise in
8
conditions
200 Elizabeth St, M5G, 2C4, 
Toronto, ON, CA 

Overview

Ur Metser practices practicing medicine in Toronto, Canada.

Metser is highly rated in 8 conditions, according to our data. Their clinical expertise encompasses Prostate Cancer, Primary Mediastinal B-Cell Lymphoma (PMBCL), Neuroendocrine Tumor, Prostatectomy, and Nephrectomy.

They are actively involved in clinical research, co-authoring 184 peer reviewed articles and participating in 8 clinical trials.

Locations

200 Elizabeth St, M5G, 2C4, Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

PSMA-PET Registry for Recurrent Prostate Cancer
PSMA-PET Registry for Recurrent Prostate Cancer
Enrollment Status: Completed
Publish Date: July 17, 2026
Intervention Type: Diagnostic test
Study Phase: Not Applicable
Combined 68Ga-DOTATATE and 18F-FDG PET/CT Imaging in Patients With Well-differentiated, G2-G3, Gastroenteropancreatic (GEP)-Neuroendocrine Tumors (NETs) - A Pilot Study
Combined 68Ga-DOTATATE and 18F-FDG PET/CT Imaging in Patients With Well-differentiated, G2-G3, Gastroenteropancreatic (GEP)-Neuroendocrine Tumors (NETs) - A Pilot Study
Enrollment Status: Active_not_recruiting
Publish Date: March 23, 2026
Intervention Type: Drug
Study Phase: Not Applicable
Princess Margaret Cancer Centre 18F-DCFPyL PET Registry
Princess Margaret Cancer Centre 18F-DCFPyL PET Registry
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Diagnostic test
Study Phase: Not Applicable
Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR
Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR
Enrollment Status: Completed
Publish Date: June 25, 2025
Intervention Type: Procedure
Study Phase: Not Applicable
A Phase 3, Non-randomized, Open Label, Multi-centre Clinical Trial to Investigate the Safety and Efficacy of [18F]PSMA-1007 Injection in Men With Suspected Persistent or Recurrent Prostate Cancer.
A Phase 3, Non-randomized, Open Label, Multi-centre Clinical Trial to Investigate the Safety and Efficacy of [18F]PSMA-1007 Injection in Men With Suspected Persistent or Recurrent Prostate Cancer.
Enrollment Status: Completed
Publish Date: February 07, 2024
Intervention Type: Diagnostic test
Study Phase: Phase 3
18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer
18F-DCFPyL PET/CT in High-grade Epithelial Ovarian Cancer
Enrollment Status: Completed
Publish Date: November 02, 2022
Intervention Type: Diagnostic test
Study Phase: Not Applicable
PROPS (PET/MRI Pre-Radiotherapy for Post-Prostatectomy Salvage)
PROPS (PET/MRI Pre-Radiotherapy for Post-Prostatectomy Salvage)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Device
Study Phase: Not Applicable
18F-Fluoroazomycin Arabinoside (FAZA) Positron Emission Tomography/Magnetic Imaging Resonance (PET/MRI) as a Biomarker of Hypoxia in Rectal Cancer: A Pilot Study
18F-Fluoroazomycin Arabinoside (FAZA) Positron Emission Tomography/Magnetic Imaging Resonance (PET/MRI) as a Biomarker of Hypoxia in Rectal Cancer: A Pilot Study
Enrollment Status: Completed
Publish Date: August 16, 2019
View 7 Less Clinical Trials

184 Total Publications

Predictors and prevalence of lateral supraclavicular lymph node metastases on [18F]FDG PET/CT in patients with locally advanced, or multifocal invasive ductal carcinoma of breast: potential impact on adjuvant radiotherapy targets.
Predictors and prevalence of lateral supraclavicular lymph node metastases on [18F]FDG PET/CT in patients with locally advanced, or multifocal invasive ductal carcinoma of breast: potential impact on adjuvant radiotherapy targets.
Journal: Frontiers in oncology
Published: June 22, 2026

Frequently Asked Questions about Ur Metser

Is Ur Metser a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Ur Metser is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Ur Metser participate in research or clinical trials?

Yes. Ur Metser has published 184 articles and abstracts on conditions like Prostate Cancer. You can view a list of Ur Metser's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Metser's expertise for a condition
ConditionClose
    View All 33 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile